Last checked at GLOBAL MARKETS ROUNDUP* Nifty futures on the Singapore Exchange was down 0.23percent, while the MSCI-Asia Pacific excluding Japan index gains 0.04 percent. * Asian share markets struggled for inspiration on Wednesday,hampered by expectations of further reductions in the U.S.Federal Reserve's stimulus and ahead of central bank meetings inJapan and Thailand. * U.S. stocks mostly rose on Tuesday, with the S&P 500 snappinga two-session decline as the materials sector rallied, thoughthe Dow fell on disappointing earnings by three of itscomponents. EVENTS/FACTORS TO WATCHEarnings on Wednesday: Larsen & Toubro and HousingDevelopment and Finance Corp. INDIAN STOCKS TO WATCHFor additional press items double click NOTE: Reuters has not verified third-party stories and does notvouch for their accuracy. India central bank moves towards monetary policy overhaul IMF sees higher global growth, warns of deflation risks Indian banks seek refuge in home loans, crowd onto HDFC'smortgage turf Cairn India under income tax lens over share sale - EconomicTimes (http://link.reuters.com/nyz26v) Unilever sticks with emerging markets as sales rebound India picks banks to sell $925 mln Axis Bank stake India's Ashok Leyland says Dec-quarter net loss 1.67 blnrupees India's Colgate Palmolive Oct-Dec net up 1.6 pct P&G to invest 15 billion rupees in India to catch up withHUL - Economic Times (http://link.reuters.com/myz26v) Bharti Airtel puts Bangladesh towers up for sale too-Economic Times (http://link.reuters.com/qyz26v) SpiceJet starts first fare war of '14, other airlines takethe cue - Economic Times (http://link.reuters.com/ryz26v) Indian drug makers gasp with relief as US regulator relaxesinhaler norms - Business Standard (http://link.reuters.com/syz26v) Tax regime: Foreign portfolio investors to be treated likeFIIs - Business Line (http://link.reuters.com/vyz26v) Suzlon looks to list its crown jewel, REpower - BusinessStandard -(http://link.reuters.com/tyz26v) (Compiled by Dipika Lalwani)
2 May 2024 19:57
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.
Read more
